PRLD: Psyros POC platform advances with strong patent wins and pivotal clinical studies ahead

About this update from Prolight Diagnostics Ab

Prolight Diagnostics advanced its Psyros POC platform, secured key patents, and reported a net loss of SEK 10.9 million in Q1 2025, with no sales and increased development costs. The company is preparing for pivotal clinical studies and a rights issue to fund commercialization.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Prolight Diagnostics Ab